Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2010 - 2026)

Jazz Pharmaceuticals' Cost of Revenue history runs 17 years deep, the most recent figure standing at $134.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 28.2% year-over-year to $134.1 million; the TTM figure through Mar 2026 stood at $532.8 million (up 17.14% YoY), while the FY2025 annual figure was $503.3 million, up 12.92% from the prior year.
• Cost of Revenue was $134.1 million for Q1 2026 at Jazz Pharmaceuticals, down from $153.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $167.4 million in Q4 2022 to a low of $95.5 million in Q1 2024.
• Historically, Cost of Revenue has averaged $121.1 million across 5 years, with a median of $116.3 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 186.85% in 2022, then tumbled 35.92% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $167.4 million in 2022, then plunged by 35.92% to $107.2 million in 2023, then advanced by 20.02% to $128.7 million in 2024, then grew by 19.28% to $153.5 million in 2025, then slipped by 12.65% to $134.1 million in 2026.
• The last three Cost of Revenue figures came in at $134.1 million (Q1 2026), $153.5 million (Q4 2025), and $128.9 million (Q3 2025), per Business Quant data.